SCHEMBL8064264

SCHEMBL8064264

NC(CCC(=O)Oc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 8/20 0.55
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
PRSS3 P35030 1/20 0.48
KIF11 P52732 4/20 0.47
SLC1A3 P43003 2/20 0.47
GRM8 O00222 1/20 0.47
GRM6 O15303 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GSR P00390 1/20 0.47
CYP1A2 P05177 1/20 0.47
GRIK1 P39086 1/20 0.47
GRM5 P41594 1/20 0.47
GRIA1 P42261 1/20 0.47
GRIA2 P42262 1/20 0.47
GRIA3 P42263 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
GRIA4 P48058 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810781 1.00 LTA4H (0.55) LTA4HPRSS1PRSS2PRSS3KIF11
SCHEMBL1810782 0.88 PRSS1 (0.47) LTA4HPRSS1PRSS2PRSS3SLC1A3
SCHEMBL4230862 0.85 SLC1A5 (0.47) LTA4HKIF11SLC1A3GRM8GRM6
SCHEMBL2266753 0.85 GRM6 (0.46) LTA4HKIF11SLC1A3GRM8GRM6
SCHEMBL28497163 0.85 PRSS1 (0.44) LTA4HPRSS1PRSS2PRSS3SLC1A3
SCHEMBL2266748 0.85 GRM6 (0.46) LTA4HKIF11SLC1A3GRM8GRM6
SCHEMBL27842369 0.84 LTA4H (0.52) LTA4HPRSS1PRSS2PRSS3KIF11
SCHEMBL10306609 0.84 ELANE (0.45) LTA4HPRSS1PRSS2PRSS3SLC1A3
SCHEMBL19491916 0.83 LTA4H (0.46) LTA4HPRSS1PRSS2PRSS3CYP1A2
SCHEMBL7782888 0.82 ALPI (0.48) LTA4HPRSS1PRSS2PRSS3KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220016251-A1 LYMPHATIC MEDIATED TRANSPORT-BASED TRIGLYCERIDE PRODRUG, AND PREPARATION METHOD THEREFOR SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2022-01-20 US disclosed
EP-3919481-A1 LYMPHATIC MEDIATED TRANSPORT-BASED TRIGLYCERIDE PRODRUG, AND PREPARATION METHOD THEREFOR Shenyang Pharmaceutical University (CN) 2021-12-08 EP disclosed
WO-2020156307-A1 LYMPHATIC MEDIATED TRANSPORT-BASED TRIGLYCERIDE PRODRUG, AND PREPARATION METHOD THEREFOR 沈阳药科大学 2020-08-06 WO disclosed
EP-0780167-B1 A method and apparatus for diffusing a chemical solution, a method and apparatus for injecting a liquid, and a method of remedying soil CANON KK (JP) 2000-06-07 EP disclosed
US-5877390-A USING GAS PRESSURE CANON KABUSHIKI KAISHA (JP) 1999-03-02 US disclosed
EP-0780167-A1 A method and apparatus for diffusing a chemical solution, a method and apparatus for injecting a liquid, and a method of remedying soil CANON KABUSHIKI KAISHA (JP) 1997-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016251-A1 LYMPHATIC MEDIATED TRANSPORT-BASED TRIGLYCERIDE PRODRUG, AND PREPARATION METHOD THEREFOR MTTP, PNLIP, MGLL LTA4H 496/4885PRSS1 930/4885PRSS2 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.